MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects
详细信息 查看全文
- 作者：U. Urner-Blocha ; 1 ; M. Urnerb ; c ; 1 ; N. Jaberg-Benteled ; A.L. Frauchigerd ; R. Dummerd ; 2 ; reinhard.dummer@usz.ch" class="auth_mail" title="E-mail the corresponding author ; S.M. Goldingerd ; 2
- 关键词：MEK inhibition ; Retinopathy ; Melanoma ; Long-term treatment ; Optical coherence tomography ; BRAF inhibition
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：65
- 期：Complete
- 页码：130-138
- 全文大小：1963 K
文摘
- •
Binimetinib is safe regarding ocular side-effects, for treatment up to 2 years.
- •
Binimetinib causes a dose- and time-dependent retinopathy with mild visual symptoms.
- •
The appearance of the lesions is related to the time elapsed since medication.
- •
The addition of a RAF inhibitor modulates the aspect of the lesion.
- •
Signs of retinal thinning without visual loss were found after long-term treatment.